Last updated: February 19, 2026
What is the current status of Almorexant's development?
Almorexant was a dual orexin receptor antagonist (DORA) developed initially by Actelion (later acquired by Johnson & Johnson) for the treatment of insomnia.
- Phase 2 trials: Conducted around 2010-2012 to evaluate efficacy and safety.
- Clinical hold: Development was discontinued in 2013 after phase 2 trials showed inconsistent efficacy and safety concerns. J&J halted further development.
- Regulatory status: No filings or approvals, and no active clinical trials since the discontinuation.
Why was Almorexant discontinued?
- Efficacy issues: Inconsistent sleep improvement in clinical trials.
- Safety concerns: Adverse events including excessive daytime sleepiness, fatigue, and potential respiratory effects.
- Market competition: Existing drugs like zolpidem, eszopiclone, and suvorexant entered the market with better safety profiles.
What are the key pharmacological features of Almorexant?
| Property |
Details |
| Mechanism |
Dual orexin receptor antagonist (OX1 and OX2) |
| Binding affinity |
High for both OX1 and OX2 receptors |
| Development phase |
Discontinued after Phase 2 |
| Dosing |
Approximately 25-50 mg daily in trials |
| Half-life |
Approximately 10 hours |
How does Almorexant compare to other orexin antagonists?
| Drug |
Receptor Activity |
Market Status |
Notable Issues |
| Suvorexant (Belsomra) |
OX1 and OX2 |
Approved in 2014 (FDA) |
Next-day sleepiness, complex dosing |
| Lemborexant (Dayvigo) |
OX1 and OX2 |
Approved in 2019 |
Slightly better tolerability metrics |
| Almorexant |
OX1 and OX2 |
Discontinued |
Efficacy, safety concerns |
Market analysis: potential and challenges
Market size
- Global sleep aid market: Estimated at USD 5 billion in 2021 and projected to grow at a compound annual growth rate (CAGR) of 6% to 7% through 2026 [[1]].
- Insomnia prevalence: Affects approximately 10-15% of adults worldwide.
Competitive landscape
- Leading drugs include benzodiazepines, non-benzodiazepine hypnotics (zolpidem, eszopiclone), and orexin antagonists (suvorexant, lemborexant).
- Suvorexant's success illustrates market acceptance of orexin receptor antagonists, despite side effects.
- Entry barriers lower for novel DORAs with improved safety profiles; early failures like Almorexant highlight the importance of safety and efficacy.
R&D considerations
- Renewed focus on orexin pathway modulation prompts interest in next-generation DORAs.
- Development costs for new orexin antagonists typically range between USD 150 million and USD 300 million per phase 2 to 3 cycle.
- Potential for non-branded, patent-expiring formulations to enter generics segment post-approval.
Market projection
- If revived with improved pharmacology, a novel orexin antagonist could capture 10-20% of the sleep aids market within 5 years.
- Revenue estimates depend on dosing regime and regional approvals; for a 10% market share, annual revenues could approach USD 1 billion globally.
Opportunities for repositioning or new development
- Address safety and efficacy limitations of Almorexant.
- Innovate on pharmacokinetics to reduce side effects.
- Explore combination therapies for comorbid insomnia and depression or anxiety.
- Leverage advances in biomarker-driven patient selection for improved outcomes.
Key challenges
- Past discontinuation indicates inherent pharmacological hurdles.
- Competitive saturation with well-established drugs.
- Regulatory scrutiny over safety, especially respiratory and next-day effects.
- Intellectual property considerations due to prior development history.
Key Takeaways
Almorexant's development was halted due to safety and efficacy concerns after phase 2 trials. The market for insomnia treatments remains strong, with orexin antagonists like suvorexant and lemborexant dominating. Future opportunities depend on innovations that surpass previous limitations, particularly improving safety profiles. Firms exploring next-generation orexin receptor antagonists may find openings, but must navigate significant R&D costs and competition.
FAQs
1. Is Almorexant available for therapeutic use?
No. Development was discontinued after phases 2 trials concluded safety and efficacy issues.
2. Can Almorexant be repurposed?
Unlikely. No ongoing clinical trials, and previous data suggest limited safety margin for re-entry.
3. How does the orexin pathway influence sleep?
It promotes wakefulness; blocking orexin receptors induces sleep, making DORAs effective sleep agents.
4. Are there ongoing efforts to develop improved orexin antagonists?
Yes. Companies are investing in next-generation molecules that enhance safety and efficacy profiles.
5. What regulatory challenges might a new drug targeting the same pathway face?
Safety concerns similar to past drugs, and the need for substantial evidence demonstrating superiority or safety improvements.
References
[1] MarketsandMarkets. (2021). Sleep Aids Market by Type, Application, Region—Global Forecast to 2026.
